AU2019217526A1 - Compositions and methods for treating cancer and immune disorders using Veillonella bacteria - Google Patents

Compositions and methods for treating cancer and immune disorders using Veillonella bacteria Download PDF

Info

Publication number
AU2019217526A1
AU2019217526A1 AU2019217526A AU2019217526A AU2019217526A1 AU 2019217526 A1 AU2019217526 A1 AU 2019217526A1 AU 2019217526 A AU2019217526 A AU 2019217526A AU 2019217526 A AU2019217526 A AU 2019217526A AU 2019217526 A1 AU2019217526 A1 AU 2019217526A1
Authority
AU
Australia
Prior art keywords
carcinoma
veillonella
protein
cell
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019217526A
Other languages
English (en)
Inventor
Baundauna BOSE
Sofia M.R. Carlton
Taylor A. Cormack
Christopher J.H. Davitt
Brian Goodman
Andrea Itano
Holly PONICHTERA
Kritika RAMANI
Maria Sizova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evelo Biosciences Inc
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AU2019217526A1 publication Critical patent/AU2019217526A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Sustainable Development (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
AU2019217526A 2018-02-06 2019-02-06 Compositions and methods for treating cancer and immune disorders using Veillonella bacteria Abandoned AU2019217526A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862626789P 2018-02-06 2018-02-06
US62/626,789 2018-02-06
US201862666944P 2018-05-04 2018-05-04
US62/666,944 2018-05-04
US201862703269P 2018-07-25 2018-07-25
US62/703,269 2018-07-25
PCT/US2019/016763 WO2019157003A1 (en) 2018-02-06 2019-02-06 Compositions and methods for treating cancer and immune disorders using veillonella bacteria

Publications (1)

Publication Number Publication Date
AU2019217526A1 true AU2019217526A1 (en) 2020-08-13

Family

ID=65767281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019217526A Abandoned AU2019217526A1 (en) 2018-02-06 2019-02-06 Compositions and methods for treating cancer and immune disorders using Veillonella bacteria

Country Status (13)

Country Link
US (2) US11090341B2 (enExample)
EP (1) EP3749340A1 (enExample)
JP (1) JP7402805B2 (enExample)
KR (1) KR20200118100A (enExample)
CN (1) CN112074283A (enExample)
AU (1) AU2019217526A1 (enExample)
BR (1) BR112020015639A2 (enExample)
CA (1) CA3090166A1 (enExample)
CO (1) CO2020010956A2 (enExample)
MX (1) MX2020008244A (enExample)
SA (1) SA520412543B1 (enExample)
TW (1) TW201945015A (enExample)
WO (1) WO2019157003A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
TW202045192A (zh) * 2019-02-22 2020-12-16 美商艾弗洛生物科技股份有限公司 細菌膜製劑
WO2021142279A1 (en) * 2020-01-10 2021-07-15 Evelo Biosciences, Inc. Compositions and methods of treatment using veillonella parvula
CN115551486A (zh) * 2020-04-17 2022-12-30 伊夫罗生物科学公司 具有改善的崩解谱的固体剂型
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
WO2022051494A1 (en) * 2020-09-03 2022-03-10 Evelo Biosciences, Inc. Compositions and methods for resolution of inflammation
TW202233214A (zh) 2020-11-06 2022-09-01 美商艾弗洛生物科技股份有限公司 使用小韋榮氏球菌細菌誘導免疫效應
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細胞外小胞調製物
WO2022191183A1 (ja) * 2021-03-08 2022-09-15 学校法人順天堂 炎症抑制作用を有する組成物及び改善剤
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2023062422A1 (en) * 2021-10-11 2023-04-20 Vastu Vihar Biotech Private Limited An anti-inflammatory composition and a method of obtaining the same
KR102859962B1 (ko) * 2021-10-20 2025-09-18 주식회사 고바이오랩 항암 활성을 갖는 베일로넬라 파르불라 균주를 이용한 암의 완화, 예방 또는 치료용 조성물
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
CN114146098A (zh) * 2021-12-31 2022-03-08 中山大学 Veillonella atypica在制备预防和/或治疗结直肠癌药物中的应用
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023234587A1 (ko) * 2022-05-30 2023-12-07 한국생명공학연구원 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도
KR102861997B1 (ko) * 2022-05-30 2025-09-22 한국생명공학연구원 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도
CN116355785A (zh) * 2022-09-29 2023-06-30 南京市儿童医院 一株小韦荣氏球菌及其在制备诊断和治疗口腔鳞状细胞癌产品中的应用
CN115990260B (zh) * 2022-12-09 2025-07-22 中国药科大学 一种用于抗肿瘤的联用组合药物
EP4658287A1 (en) * 2023-01-30 2025-12-10 MRM Health N.V. Microbial compositions for treating joint inflammation
TWI859033B (zh) * 2023-12-18 2024-10-11 安益藥業股份有限公司 一種診斷犬科動物胰臟炎的方法與試劑組與一種使用醯基肉鹼作為診斷犬科動物胰臟炎之用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57139090A (en) * 1981-02-19 1982-08-27 Toyama Chem Co Ltd Carcinostatic substance tv-110, its preparation and carcinostatic agent containing the same
JPH04330016A (ja) * 1991-05-01 1992-11-18 Rikagaku Kenkyusho 過酸化脂質低下剤
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
EP0991761B1 (en) * 1997-08-21 2008-01-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
CA2571805C (en) * 2006-10-27 2018-05-01 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2015038731A1 (en) * 2013-09-12 2015-03-19 The Johns Hopkins University Biofilm formation to define risk for colon cancer
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016040074A1 (en) * 2014-09-11 2016-03-17 Drexel University Maximizing production of hydrogen from waste materials by active removal of hydrogen
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
SE1550189A1 (en) * 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
WO2016141454A1 (en) * 2015-03-12 2016-09-15 The University Of British Columbia Bacterial compositions and methods of use thereof
KR101734653B1 (ko) * 2015-06-23 2017-05-11 서울대학교산학협력단 아미노글리코시드계 항생제 및 프로바이오틱스를 포함하는 아프타 구내염 예방 또는 치료용 약학적 조성물
CN111148531A (zh) * 2017-09-08 2020-05-12 伊夫罗生物科学公司 细菌胞外囊泡
WO2020252144A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Secreted microbial extracellular vesicles

Also Published As

Publication number Publication date
MX2020008244A (es) 2020-09-25
US20210330718A1 (en) 2021-10-28
KR20200118100A (ko) 2020-10-14
JP2021512133A (ja) 2021-05-13
JP7402805B2 (ja) 2023-12-21
BR112020015639A2 (pt) 2021-03-30
CN112074283A (zh) 2020-12-11
SA520412543B1 (ar) 2023-12-11
EP3749340A1 (en) 2020-12-16
CO2020010956A2 (es) 2020-10-30
CA3090166A1 (en) 2019-08-15
WO2019157003A1 (en) 2019-08-15
WO2019157003A9 (en) 2020-03-19
US20190350987A1 (en) 2019-11-21
US11090341B2 (en) 2021-08-17
TW201945015A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
US10702561B2 (en) Pharmaceutical compositions comprising a Blautia strain
US11090341B2 (en) Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
US20220211773A1 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
US20230405058A1 (en) Extracellular vesicles from prevotella
US20210052669A1 (en) Compositions and methods for treating immune disorders using lachnospiraceae bacteria
US20190192585A1 (en) Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
EP3982987A1 (en) Processed microbial extracellular vesicles
WO2019178487A2 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178494A1 (en) Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178490A1 (en) Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019169160A1 (en) Compositions and methods for treating cancer using ruminococcus gnavus
WO2019169168A1 (en) Compositions and methods for treating cancer using agathobaculum
WO2019169181A1 (en) Compositions and methods for treating cancer using lactobacillus salivarius
WO2020006216A1 (en) Compositions and methods of treating cancer using neisseria bacteria
WO2019169138A1 (en) Compositions and methods for treating cancer using paraclostridium benzoelyticum
WO2019169143A1 (en) Compositions and methods for treating cancer using turicibacter sanguinis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application